LATEST HEADLINESView All Archive
- Cytokinetics Announces Presentation Relating to Tirasemtiv and BENEFIT-ALS at International Symposium on ALS/MND December 2,2013 December 2, 2013, 7:31 a.m. ET Wall St. Journal Cytokinetic
- Neuraltus seeks $30m for Phase IIB October 11,2013 Oct. 9, 2013. SF Business Times. Refined Trial Endpoint
- Neuraltus Names Richard L. Casey as President and CEO October 11,2013 Oct. 8, 2013. Newswire: One of the good guys.
- Looking for lessons in cancer’s ‘miracle’ responders September 23,2013 Sept. 15, 2013. Reuters: Genetically identifying respo
- Biogen Acquires Rights to Isis AntiSense September 9,2013 Sept. 9th Reuters. ALS-ETF Partners with Denovo Biomarkers for Pharmacogenomic Research July 8,2013 Genetic Analysis of Responders in Expanded Access Programs
- Cytokinetics Boosts Size of Phase 2B Tirasemtiv Trial in ALS July 8,2013 Swift Response after Vendor’s Shipping Error
- Cystic Fibrosis Drugs Win FDA’s Breakthrough Therapy Designation July 8,2013 Provisional Approval after Phase I; Why Not in ALS?
- Demand Grows for Early Access to Promising Cancer Drugs August 19,2013 In recent years, expanded access programs have allowed thous
- Genervon Gets FDA Go-Ahead for Phase II Trial in ALS July 8,2013 Multi-Target Master Regulatory Protein
PERSPECTIVESView All Archive
- Using EAP Data for Biomarker Discovery April 8, 2014 Newest FAQ: What do EAPs and genetic research have in comm
- Four Myths About EAPs October 7, 2013 ALS-ETF: If you have looked into Expanded Access, chances
- Early Stage Development in Orphan Space Best Left to Small-Co September 24, 2013 By Anusha Kambhampaty; FT. Sept. 23rd, 2013. Comments
- Trial Participants Left High and Dry September 7, 2013 Sept. 7, 2013, ALS-Advocacy: Envision a person with ALS wh
- Destined to Die for Not Fitting In? September 4, 2013 I'm angry because I'm being punished for living too long...
- Our Friend Barbara Brenner
September 4, 2013 May 2013: Barbara Brenner brought lessons from the ca
- Bayer Opens Expanded Access Program for Cancer Drug August 22, 2013 May 2012: Bayer, the maker of an experimental drug for col
- Early Approvals for Drugs to Treat Life Threatening Diseases August 22, 2013 Feb. 2013: Andy von Eschenbach for Easing Efficacy Requireme
- Prize4Life and Knopp Neurosciences Announce Donation of EMPOWER August 22, 2013 June 2013-- Prize4Life and Knopp Neurosciences Inc. today an
- Pharma Exec, David Vance on Expanded Access August 22, 2013 Sept. 2011: Interview with Noven Pharma's Compliance Direc
©2014: alsetf.org / all rights reserved | PIXELS CRAFTED by Avion technology, inc.